Incyte Corp., of Wilmington, Del. announced that preliminary results from an ongoing phase I/II study of INCB24360, its oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, combined with ipilimumab in patients with unresectable or metastatic melanoma, showed the combination was generally well tolerated and produced evidence of clinical response.